Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,716.5 12/08/16
52 week low1,249.5 30/09/15
52 week change 397.0 (32.08%)
4 week volume148,993,280 04/09/16

Latest NewsMore

Director/PDMR Shareholding

RNS Number: 2016L GlaxoSmithKline PLC 29 September 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr K Slaoui b) Position/status PCA of Dr M M Slaoui (Chairman, Global Vaccines) c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission...

GSK completes sale of holding in Aspen

RNS Number: 1740L GlaxoSmithKline PLC 29 September 2016 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION...

GSK intends to sell remaining holding in Aspen

RNS Number: 1269L GlaxoSmithKline PLC 28 September 2016 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION...

Director/PDMR Shareholding

RNS Number: 8628K GlaxoSmithKline PLC 26 September 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr R G Connor b) Position/status President, Global Manufacturing & Supply c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allow...

Director/PDMR Shareholding

RNS Number: 8619K GlaxoSmithKline PLC 26 September 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr K Slaoui b) Position/status PCA of Dr M M Slaoui (Chairman, Global Vaccines) c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission...

GSK confirms submission for RA drug

GlaxoSmithKline has confirmed a US regulatory submission for sirukumab in rheumatoid arthritis. GSK says a biologics...

US Regulatory Submission for sirukumab in RA

RNS Number: 6995K GlaxoSmithKline PLC 23 September 2016 Issued: 23 September 2016, London UK - LSE Announcement GSK announces US regulatory submission for sirukumab in rheumatoid arthritis GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Adminis...

Shell's 70-year dividend record at risk

Shell hasn't cut the dividend since WW2, but these fund managers think it will have to. Lee Wild finds out why they've sol...

Fundamental DataMore

P/E ratio9.378
EPS174.3
Dividend yield4.894 %

Latest discussion posts More

  • Re: sirukumab for rheumatoid arthritis US su...

    It's good news, but the pedant in me wonders if it's possible to have a "moderate" blockbuster ? BB
    27-Sep-2016
    Boring Bernie
  • sirukumab for rheumatoid arthritis US submission

    News on Friday 23 Sep. GSK has submitted sirukumab for US regulatory approval to treat patients suffering from moderate to severely active rheumatoid arthritis. This has ...
    27-Sep-2016
    bloppy
  • Re: NEW CEO

    Conversely, with the vacuum left at the top of consumer by Walmsley, who is going to be big enough and strong enough to step in to her role and prove that it can be run better ...
    21-Sep-2016
    bloppy

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
VODAFONE GRP.35%
BP34%
RDS 'B'31%
NATIONAL GRID31%
LLOYDS GRP.29%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK